Assess Terlipressin for Hepatorenal Syndrome

Terlipressin (Terlivaz) will be the first FDA-approved med for hepatorenal syndrome with acute kidney injury (HRS-AKI).

HRS-AKI typically occurs in patients with cirrhosis and ascites who develop splanchnic vasodilation. This causes decreased perfusion to the kidneys.

The best treatment is a liver transplant...but many patients don’t qualify for or live long enough to get a transplant.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote